<DOC>
	<DOCNO>NCT02306005</DOCNO>
	<brief_summary>The aim study evaluate effect insulin therapy patient newly diagnose type 1 diabetes quantitative qualitative change plasma lipoprotein , particular emphasis HDL metabolism , analysis factor determine effect insulin therapy lipid profile.The study plan cover minimum 100 people newly diagnose type 1 diabetes lead prospective observation group ( minimum 5-10 year ) . Patients assess : first hospitalization moment diagnosis ( prior introduction insulin treatment ) , 3 week , 6 month 12 month insulin therapy . Further observation plan annual interval . In addition , study group constant monitoring metabolic evaluation every three month Outpatient Clinic . During follow-up assessed parameter evaluate metabolism plasma lipoprotein fraction subfractions HDL : 1 . The concentration apolipoprotein : include A-I , A-II , A-IV , C ( II III ) , D E 2 . Electrophoresis plasma lipoproteins 3 . Electrophoresis HDL 4 . The activity enzymes : acyltransferase lecithin : cholesterol ( LCAT ) plasma lipoprotein lipase Moreover , evaluation factor may potentially modify relation insulin therapy lipoproteins assessed 1 . Anthropometric data marker insulin resistance ( BMI , waist-hip ratio , estimate rate glucose distribution , VAI index , body fat , blood pressure ) , 2 . Metabolic management diabetes , , 3 . Protein glycation end product 4 . The concentration plasma adipokines . Expected impact research project development science , civilization society The obtain result allow assess impact exogenous insulin quantitative qualitative change metabolism lipoproteins serum patient type 1 diabetes . Understanding etiopathogenesis phenomenon factor affect seem important treatment patient type 1 diabetes , insulin treatment choice dosage adjustment appear extremely important . Remains unknown whether change lipoprotein profile result begin insulin therapy factor influence . Selecting group patient less favorable lipoprotein profile may allow good metabolic control , thus affect quality length life patient . These study assess impact therapeutic action diagnosis disease long-term consequence , development chronic complication .</brief_summary>
	<brief_title>Insulin Therapy Lipoproteins ' Profile Type 1 Diabetes .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>New onset type 1 diabetes treatment insulin . Written consent participate study . There medical condition , additional drug beyond insulin medical condition , additional drug beyond insulin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>diabetes mellitus type 1 , insulin therapy , lipoprotein , HDL</keyword>
</DOC>